iPlex
mecasermin rinfabate [rDNA origin]
Treatment for Primary IGF-1 DeficiencyFDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
RICHMOND, Va., March 10, 2005 - Insmed Incorporated (NASDAQ: INSM) announced today that the Company has received the acceptance to file notification from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for its drug candidate SomatoKine (mecasermin rinfabate), a novel once-daily IGF-I therapy for the treatment of growth hormone insensitivity syndrome (GHIS). It is expected that the FDA will take action on the application no later than November 3, 2005.
The FDA previously granted SomatoKine, an IGF-I therapy, orphan drug designation, a designation conferred upon investigational products for diseases that affect fewer than 200,000 patients in the United States. Products with orphan drug designation that are the first to be approved for a specific indication have seven years market exclusivity within the United States.
More on SomatoKine
Insmed's SomatoKine is a proprietary delivery composition of
insulin-like growth factor I (IGF-I). The novel compound is
administered as a subcutaneous injection, which can restore IGF-I
levels to physiologically relevant levels. On July 20, Insmed
provided the top-line results from a six-month data analysis of the
pivotal Phase III GHIS clinical trial showing a statistically
significant increase (p<0.0001) in height velocity in children
receiving SomatoKine as a once-daily injection.
In diabetic subjects, administration of SomatoKine demonstrated a significant improvement in blood sugar control and a significant reduction in daily insulin use. Following severe burn injury, in both children and adults, administration of SomatoKine demonstrated a significant improvement in muscle protein synthesis and a significant reduction in the inflammatory response associated with the trauma. In recovery from hip fractures, administration of SomatoKine demonstrated a significant improvement in functional recovery and bone mineral density.
About Insmed
Insmed is a biopharmaceutical company focused on the discovery and
development of drug candidates for the treatment of metabolic
diseases and endocrine disorders with unmet medical needs.
For more information, please visit www.insmed.com.
Related Articles:
iPlex Insmed Incorporated - Treatment for Severe Primary IGF-1 Deficiency - December 12, 2005
FDA to Review Insmed's Complete Response to Approvable Letter for iPlex - October 25, 2005
Insmed Submits Response to FDA Approvable Letter for iPlex - October 17, 2005
Insmed Receives Approvable Letter for iPlex - September 27, 2005
FDA Extends PDUFA Date for SomatoKine to October 3, 2005 - June 10, 2005
Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome - January 3, 2005
New Drug Applications Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
